Acasti Pharma (TSXV:ACST) 5-Year EBITDA Growth Rate : 47.90% (As of Dec. 2023)

View and export this data going back to 2011. Start your Free Trial

What is Acasti Pharma 5-Year EBITDA Growth Rate?

Acasti Pharma's EBITDA per Share for the three months ended in Dec. 2023 was C$-0.09.

During the past 3 years, the average EBITDA Per Share Growth Rate was 42.80% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 47.90% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 26.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Acasti Pharma was 57.50% per year. The lowest was -31.00% per year. And the median was 7.90% per year.

Competitive Comparison of Acasti Pharma's 5-Year EBITDA Growth Rate

For the Biotechnology subindustry, Acasti Pharma's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Acasti Pharma's 5-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Acasti Pharma's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Acasti Pharma's 5-Year EBITDA Growth Rate falls into.

Acasti Pharma 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Acasti Pharma (TSXV:ACST) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Acasti Pharma 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Acasti Pharma's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Acasti Pharma (TSXV:ACST) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acasti Pharma Inc (TSXV:ACST) » Definitions » 5-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

ACST:USA A1P0:Germany

Address

3009 Boulevard de la Concorde East, Suite 102, Laval, QC, CAN, H7E 2B5

Website

https://www.acastipharma.com

Acasti Pharma Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. Its novel drug delivery technologies have the potential to improve the performance of marketed drugs by achieving faster onset of action, enhanced efficacy, reduced side effects, and more convenient drug delivery all of which could help to increase treatment compliance and improve patient outcomes.